Latest Nyrada (ASX:NYR) News

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.